Yr Athro Colin Dayan

(e/fe)

BSc, MBChB, PhD, FRCP

2026

• Robinson, E. et al., 2026. Scrnaseq of thyroid eye disease orbital fat demonstrates fibroblast thyroid hormone signaling and sparc production [Abstract]. Endocrine Abstracts 119 OP01-03. (10.1530/endoabs.119.op-01-03)
• Allen, L. A. , Mahmood, Z. S. and Dayan, C. M. 2026. New therapeutic approaches in diabetes treatment: immune interventions. In: Gupta, S. and Gupta, A. eds. A Health Care Professionals Guide on Digital Diabetes. Springer Nature. , pp.465-491. (10.1007/978-3-032-24854-1_28)
• Ibad, M. M. et al., 2026. Graves' disease: Prospective up to 10‐year outcome for 100 consecutive individuals at a single centre [Letter]. Clinical Endocrinology 105 (1), pp.122-125. (10.1111/cen.70148)
• Taylor, P. N. et al. 2026. Relationship between participant-reported outcomes, residual beta cell function and metabolic parameters in youth with newly diagnosed type 1 diabetes. Diabetologia (10.1007/s00125-026-06798-z)
• Tteralli, N. et al. 2026. Beta cell specific cell free DNA and trypsinogen for the diagnosis of rejection in pancreas transplantation: update on the EMPAR study [Abstract]. American Journal of Transplantation 26 (7 S1), pp.S332. (10.1016/j.ajt.2026.05.385)
• Mitchell, N. et al., 2026. Reducing the impact of diabetic foot ulcers (REDUCE): study protocol for an effectiveness and cost-effectiveness randomised controlled trial with embedded process evaluation. BMJ Open 16 (5) e118771. (10.1136/bmjopen-2026-118771)
• Dunseath, G. J. et al., 2026. Serial dried blood spot c-peptide sampling, but not urine c-peptide-to-creatinine ratio, detects early preservation of β-cell function in new-onset type 1 diabetes: experience from the USTEKID trial. Diabetes Care 49 (7), pp.1-8. (10.2337/dc25-2896)
• Heald, A. H. et al., 2026. Evaluating the link between thyroid function test results and Levothyroxine dose in the management of hypothyroidism: Can we improve dosing regimes?. Clinical Endocrinology 104 (4), pp.372-385. (10.1111/cen.70074)
• Tatovic, D. and Dayan, C. 2026. Clinical immunologic interventions for the treatment of type 1 diabetes: challenges, choice, and timing of immunomodulators. Cold Spring Harbor Perspectives in Medicine 16 (4) a041597. (10.1101/cshperspect.a041597)
• Galderisi, A. et al., 2026. Baseline insulin secretion determines response to Abatacept in stage 1 type 1 diabetes. Diabetes 75 (2), pp.229-240. (10.2337/db25-0801)

2025

• McNabb, C. B. et al. 2025. Controlled antenatal thyroid screening study III: effects of gestational thyroid status on brain microstructure. The Journal of Clinical Endocrinology & Metabolism 110 (12), pp.3322-3330. (10.1210/clinem/dgaf277)
• Bahl, S. et al. 2025. Risk of death and adverse effects in patients on Liothyronine: a multi-source systematic review and meta-analysis. The Journal of Clinical Endocrinology & Metabolism 110 (11), pp.3278-3288. (10.1210/clinem/dgaf449)
• Michels, A. W. et al., 2025. Autoimmune type 1 diabetes in the era of disease‐modifying immune therapy. Diabetes/Metabolism Research and Reviews 41 (7) e70091. (10.1002/dmrr.70091)
• Swaby, R. et al., 2025. Testing methods used to predict disease progression in children with early‐stage type 1 diabetes: A systematic review and meta‐analysis. Diabetic Medicine 42 (9) e70077. (10.1111/dme.70077)
• Dayan, C. M. et al. 2025. System failure in type 1 diabetes: what stakeholders need to know to expedite therapeutic options. Diabetes Spectrum 38 (4), pp.467-475. (10.2337/ds25-0024)
• Perazzolo, S. et al., 2025. Automated oral minimal models for rapid estimation of insulin sensitivity and beta-cell responsivity in large-scale data sets: a validation study. Journal of Diabetes Science and Technology (10.1177/19322968251365274)
• Swaby, R. et al., 2025. A UK healthcare professional survey on the islet autoantibody status of children and young people with pre‐stage 3 type 1 diabetes, on behalf of the British Society for Paediatric Endocrinology and Diabetes [Letter]. Diabetic Medicine 42 (8) e70069. (10.1111/dme.70069)
• Sims, E. K. et al., 2025. Novel approach for assessing outcomes of type 1 diabetes prevention trials over a fixed time interval. Diabetes db250310. (10.2337/db25-0310)
• Quinn, L. M. et al., 2025. Protocol for a feasibility and acceptability study for UK general population paediatric type 1 diabetes screening—the EarLy Surveillance for Autoimmune diabetes ( ELSA ) study. Diabetic Medicine 42 (5) e15490. (10.1111/dme.15490)
• Dayan, C. M. et al. 2025. Safety of teplizumab in stage 2 and stage 3 type 1 diabetes: Integrated analysis of clinical trials. Diabetologie und Stoffwechsel 20 (S 01) S55. (10.1055/s-0045-1807462)
• Herold, K. C. et al., 2025. PROTECT per-protocol analysis: Preservation of β-cell function in children and adolescents with newly diagnosed type 1 diabetes stage 3. Diabetologie und Stoffwechsel 20 (S 01), pp.S40-S41. (10.1055/s-0045-1807433)
• Schnell, O. et al., 2025. CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes. Cardiovascular Diabetology 24 (1) 187. (10.1186/s12933-025-02700-0)
• Heald, A. H. et al., 2025. How does thyroid hormone profile differ on and off replacement treatment?. Clinical Endocrinology 102 (4), pp.490-495. (10.1111/cen.15185)
• Carter, K. et al., 2025. The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT. Efficacy and Mechanism Evaluation 12 (1), pp.1-66. (10.3310/fqln7416)

2024

• Martino, M. et al. 2024. Revisiting the pattern of loss of β-cell function in preclinical Type 1 Diabetes. Diabetes 73 (11), pp.1769-1779. db240163. (10.2337/db24-0163)
• Wych, J. et al. 2024. Investigating the effect of verapamil on preservation of beta-cell function in adults with newly diagnosed type 1 diabetes mellitus (Ver-A-T1D): protocol for a randomised, double-blind, placebo-controlled, parallel-group, multicentre trial. BMJ Open 14 (11) e091597. (10.1136/bmjopen-2024-091597)
• Scudder, C. et al., 2024. General population screening for type 1 diabetes using islet autoantibodies at the preschool vaccination visit: a proof-of-concept study (the T1Early study). Archives of Disease in Childhood 109 , pp.812-817. (10.1136/archdischild-2023-326697)
• Swaby, R. et al., 2024. A study to determine a capillary alternative to the gold standard oral glucose tolerance test - Protocol. Wellcome Open Research 9 601. (10.12688/wellcomeopenres.23028.1)
• Tatovic, D. et al. 2024. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial. Nature Medicine 30 , pp.2657-2666. (10.1038/s41591-024-03115-2)
• Heald, A. H. et al., 2024. Liothyronine (LT3) prescribing in England: Are cost constraints inhibiting guideline implementation?. Clinical Endocrinology 101 (1), pp.62-68. (10.1111/cen.15061)
• Scholz, A. et al. 2024. Controlled antenatal thyroid screening study III: Effects of gestational thyroid status on adolescent brain morphology. The Journal of Clinical Endocrinology & Metabolism (10.1210/clinem/dgae338)
• Heald, A. H. et al., 2024. Natural desiccated thyroid for the treatment of hypothyroidism?. Frontiers in Endocrinology 14 1309159. (10.3389/fendo.2023.1309159)
• Allen, L. et al. 2024. A study of relative maternal protection against type 1 diabetes in offspring: Statistical analysis plan. Elsevier

2023

• Galderisi, A. et al., 2023. Quantifying beta cell function in the preclinical stages of type 1 diabetes. Diabetologia 66 , pp.2189-2199. (10.1007/s00125-023-06011-5)
• Heald, A. et al., 2023. Liothyronine prescribing in England: Costs versus need. The Lancet 402 (10417), pp.2074-2075. (10.1016/S0140-6736(23)01792-0)
• Premawardhana, L. D. et al. 2023. Designing a combined Liothyronine (LT3), L-thyroxine (LT4) trial in symptomatic hypothyroid subjects on LT4 – the importance of patient selection, choice of LT3 and trial design. Frontiers in Endocrinology 14 1282608. (10.3389/fendo.2023.1282608)
• Taylor, P. N. et al. 2023. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis. The Lancet Diabetes & Endocrinology 11 (12), pp.915-925. (10.1016/S2213-8587(23)00267-X)
• Allen, L. A. et al. 2023. Maternal type 1 diabetes and relative protection against offspring transmission. Lancet Diabetes and Endocrinology 11 (10), pp.755-767. (10.1016/S2213-8587(23)00190-0)
• Taylor, P. et al. 2023. Factors predicting long-term outcome and the need for surgery in Graves orbitopathy: Extended follow-up from the CIRTED trial. The Journal of Clinical Endocrinology & Metabolism 108 (10), pp.2615-2625. (10.1210/clinem/dgad084)
• Ramos, E. L. et al., 2023. Teplizumab and β-Cell function in newly diagnosed Type 1 diabetes. New England Journal of Medicine 389 (23), pp.2151-2161. (10.1056/nejmoa2308743)
• Hanna, S. J. et al. 2023. Single-cell RNAseq identifies clonally expanded antigen-specific T-cells following intradermal injection of gold nanoparticles loaded with diabetes autoantigen in humans. Frontiers in Immunology 14 1276255. (10.3389/fimmu.2023.1276255)
• Okosieme, O. et al. 2023. Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone β (RTHβ): a linked-record cohort study. The Lancet Diabetes & Endocrinology 11 (9), pp.657-666. (10.1016/S2213-8587(23)00155-9)
• Ahluwalia, R. et al., 2023. Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement. Clinical Endocrinology 99 (2), pp.206-216. (10.1111/cen.14935)
• Cantley, J. et al., 2023. Islet cells in human type 1 diabetes: from recent advances to novel therapies ? a symposium-based roadmap for future research. Journal of Endocrinology 259 (1) e230082. (10.1530/JOE-23-0082)
• Mulder, T. A. et al., 2023. Genetic determinants of thyroid function in children. European journal of endocrinology 189 (2), pp.164-174. (10.1093/ejendo/lvad086)
• Holman, N. et al., 2023. National trends in hyperglycemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a challenge due to age or stage of development, or is new thinking about service provision needed?. Diabetes Care 46 (7), pp.1404–1408. (10.2337/dc23-0180)
• Van Rampelbergh, J. et al., 2023. First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes. BMC Medicine 21 (1) 190. (10.1186/s12916-023-02900-z)
• Taylor, P. et al. 2023. Age-related variation in thyroid function – a narrative review highlighting important implications for research and clinical practice. Thyroid Research 16 7. (10.1186/s13044-023-00149-5)
• Dayan, C. M. et al. 2023. Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies. Multiple Sclerosis Journal - Experimental, Translational and Clinical 9 1. (10.1177/20552173221142741)
• Quinn, L. M. et al., 2023. What does the licensing of teplizumab mean for diabetes care?. Diabetes, Obesity and Metabolism (10.1111/dom.15071)
• Tatovic, D. , Narendran, P. and Dayan, C. M. 2023. A perspective on treating type 1 diabetes mellitus before insulin is needed. Nature Reviews Endocrinology 19 , pp.361-370. (10.1038/s41574-023-00816-5)
• Thomas, N. J. et al., 2023. Age of diagnosis does not alter the presentation or progression of robustly defined adult-onset type 1 diabetes.. Diabetes Care (10.2337/dc22-2159)

2022

• French, R. et al. 2022. Educational attainment and childhood-onset type 1 diabetes. Diabetes Care 45 (12), pp.2852–2861. (10.2337/dc21-0693)
• Perros, P. et al., 2022. Post-radioiodine Graves' management: the PRAGMA study. Clinical Endocrinology 97 (5), pp.664-675. (10.1111/cen.14719)
• Taylor, P. N. et al. 2022. Prescribing costs of hypoglycaemic agents and associations with metabolic control in Wales; a national analysis of primary care data. Diabetic Medicine 39 (9) e14908. (10.1111/dme.14908)
• Tatovic, D. et al. 2022. Diagnosing Type 1 diabetes in adults: Guidance from the UK T1D Immunotherapy consortium. Diabetic Medicine 39 (7) e14862. (10.1111/dme.14862)
• Agrawal, M. et al., 2022. Antithyroid drug therapy in pregnancy and risk of congenital anomalies: Systematic review and meta-analysis. Clinical Endocrinology 96 (6), pp.857-868. (10.1111/cen.14646)
• Sims, E. K. et al., 2022. Screening for type 1 diabetes in the general population: a status report and perspective. Diabetes 71 (4), pp.610–623. (10.2337/dbi20-0054)
• Quinn, L. M. et al., 2022. EarLy Surveillance for Autoimmune diabetes: protocol for a qualitative study of general population and stakeholder perspectives on screening for type 1 diabetes in the UK (ELSA 1). BMJ Open Diabetes Research and Care 10 (2) e002750. (10.1136/bmjdrc-2021-002750)
• Liang, S. et al., 2022. Relationship between thyroid hormones and metabolic syndrome in a normal thyroid function population in Western China. Chinese Medical Journal 135 (3), pp.350-352. (10.1097/CM9.0000000000001553)
• Tatovic, D. et al. 2022. Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in Type 1 diabetes. Immunotherapy Advances 2 (1) ltac002. (10.1093/immadv/ltac002)

2021

• Allen, L. A. and Dayan, C. M. 2021. Immunotherapy for type 1 diabetes. British Medical Bulletin 140 (1), pp.76–90. (10.1093/bmb/ldab027)
• Draman, M. S. et al. 2021. Expression of endogenous putative TSH binding protein in orbit. Current Issues in Molecular Biology 43 (3), pp.1794-1804. (10.3390/cimb43030126)
• Heald, A. H. et al., 2021. Is there a role for natural desiccated thyroid in the treatment of levothyroxine unresponsive hypothyroidism? Results from a consecutive case series. International Journal of Clinical Practice 75 (12) e14967. (10.1111/ijcp.14967)
• Zhang, L. et al. 2021. The role of mitochondria-linked fatty-acid uptake-driven adipogenesis in Graves’ Orbitopathy. Endocrinology 162 (12) bqab188. (10.1210/endocr/bqab188)
• Draman, M. S. et al., 2021. Orbital signaling in Graves' orbitopathy. Frontiers in Endocrinology 12 739994. (10.3389/fendo.2021.739994)
• Bartalena, L. et al., 2021. The 2021 European group on graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves’ orbitopathy. European Journal of Endocrinology 185 (4), pp.G43-G67. (10.1530/EJE-21-0479)
• Gregory, J. W. et al. 2021. Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol. BMJ Open 11 (10) e049595. (10.1136/bmjopen-2021-049595)
• Hanna, S. J. et al. 2021. Insights from single cell RNA sequencing Into the immunology of type 1 diabetes- cell phenotypes and antigen specificity. Frontiers in Immunology 12 751701. (10.3389/fimmu.2021.751701)
• Stedman, M. et al., 2021. Liothyronine and levothyroxine prescribing in England: A comprehensive survey and evaluation. International Journal of Clinical Practice 75 (9) e14228. (10.1111/ijcp.14228)
• Dayan, C. M. et al. 2021. Preventing type 1 diabetes in childhood. Science 373 (6554), pp.506-510. (10.1126/science.abi4742)
• Stedman, M. et al., 2021. Trends in costs and prescribing for liothyronine and levothyroxine in England and Wales 2011-2020. Clinical Endocrinology 94 (6), pp.980-989. (10.1111/cen.14414)
• Siah, Q. Z. et al. 2021. Referral rates of patients with diabetes to secondary care are inversely related to the prevalence of diabetes in each primary care practice and confidence in treatment, not to HbA1c level. Primary Care Diabetes 15 (3), pp.513-517. (10.1016/j.pcd.2021.02.004)
• Singh, R. K. et al. 2021. Using gold nanoparticles for enhanced intradermal delivery of poorly soluble auto-antigenic peptides. Nanomedicine: Nanotechnology, Biology and Medicine 32 102321. (10.1016/j.nano.2020.102321)
• Jonklaas, J. et al., 2021. Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: a consensus document. Thyroid Journal Program 31 (2), pp.156-182. (10.1089/thy.2020.0720)
• Lam, A. , Dayan, C. and Herold, K. C. 2021. A little help from residual β cells has long-lasting clinical benefits. Journal of Clinical Investigation 131 (3) e143683. (10.1172/JCI143683)
• Delles, C. et al., 2021. Announcing the first AoP webinar: 'Can evidence-based medicine survive in a pandemic'?. QJM: An International Journal of Medicine 114 (1), pp.11-12. (10.1093/qjmed/hcaa287)
• Tatovic, D. and Dayan, C. M. 2021. Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes. Diabetic Medicine 38 e14696. (10.1111/dme.14696)

2020

• Zhang, L. et al. 2020. Distinctive features of orbital adipose tissue (OAT) in Graves' orbitopathy. International Journal of Molecular Sciences 21 (23) 9145. (10.3390/ijms21239145)
• Lee, V. et al., 2020. A survey of current practices by the British Oculoplastic Surgery Society (BOPSS) and recommendations for delivering a sustainable multidisciplinary approach to thyroid eye disease in the United Kingdom. Eye 34 , pp.1662-1671. (10.1038/s41433-019-0664-z)
• Muller, I. et al. 2020. CATS II long-term anthropometric and metabolic effects of maternal sub-optimal thyroid function in offspring and mothers. Journal of Clinical Endocrinology and Metabolism 105 (7) dgaa129. (10.1210/clinem/dgaa129)
• Hanna, S. J. et al. 2020. Slow progressors to type 1 diabetes lose islet autoantibodies over time, have few islet antigen-specific CD8+ T cells and exhibit a distinct CD95hi B cell phenotype. Diabetologia 63 , pp.1174-1185. Diabetologia volume 63, pages1174–1185(2020). (10.1007/s00125-020-05114-7)
• Arikat, F. et al. 2020. Targeting proinsulin to local immune cells using an intradermal microneedle delivery system; a potential antigen-specific immunotherapy for type 1 diabetes. Journal of Controlled Release 322 , pp.593-601. (10.1016/j.jconrel.2020.02.031)
• Derakhshan, A. et al., 2020. Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis. Lancet Diabetes and Endocrinology 8 (6), pp.501-510. (10.1016/S2213-8587(20)30061-9)
• Allen, L. A. et al. 2020. Pregnancy in teenagers diagnosed with type 1 diabetes mellitus in childhood: a national population based e-cohort study. Diabetologia 63 , pp.799-810. (10.1007/s00125-019-05063-w)
• Hales, C. et al. 2020. Controlled antenatal thyroid screening II: Effect of treating maternal sub-optimal thyroid function on child behaviour. Journal of Clinical Endocrinology and Metabolism 105 (3) dgz098. (10.1210/clinem/dgz098)
• Okosieme, O. E. , Taylor, P. N. and Dayan, C. M. 2020. Should radioiodine now be first line treatment for Graves' disease?. Thyroid Research 13 (1) 3. (10.1186/s13044-020-00077-8)
• Oakley, N. J. et al. 2020. Type 1 diabetes mellitus and educational attainment in childhood: a systematic review. BMJ Open 10 (1) e033215. (10.1136/bmjopen-2019-033215)

2019

• Taylor, P. N. et al. 2019. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nature Reviews Endocrinology 16 (2), pp.104-116. (10.1038/s41574-019-0305-4)
• Yang, J. H. M. et al., 2019. Phenotypic analysis of human lymph nodes in subjects with new-onset type 1 diabetes and healthy individuals by flow cytometry. Frontiers in Immunology 10 , pp.-. 2547. (10.3389/fimmu.2019.02547)
• Taylor, P. N. et al. 2019. Combination thyroid hormone replacement; knowns and unknowns. Frontiers in Endocrinology 10 706. (10.3389/fendo.2019.00706)
• Dayan, C. M. et al. 2019. Changing the landscape for type 1 diabetes: the first step to prevention. Lancet 394 (10205), pp.1286-1296. (10.1016/S0140-6736(19)32127-0)
• Powell, W. et al. 2019. Detecting autoreactive B cells in the peripheral blood of people with type 1 diabetes using ELISpot. Journal of Immunological Methods 471 , pp.61-65. (10.1016/j.jim.2019.05.007)
• Korevaar, T. I. M. et al., 2019. Association of thyroid function test abnormalities and thyroid autoimmunity with preterm birth: a systematic review and meta-analysis. Journal of the American Medical Association 322 (7), pp.632-641. (10.1001/jama.2019.10931)
• Muller, I. et al. 2019. 2019 European thyroid association guidelines on the management of thyroid dysfunction following immune reconstitution therapy. European Thyroid Journal 8 (4), pp.173-185. (10.1159/000500881)
• Pearce, S. H. et al., 2019. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism: a phase I study. Thyroid 29 (7), pp.1003-1011. (10.1089/thy.2019.0036)
• Wilson, N. et al., 2019. Role of hyaluronan in human adipogenesis: Evidence from in-vitro and in-vivo studies. International Journal of Molecular Sciences 20 (11) 2675. (10.3390/ijms20112675)
• Dul, M. et al. 2019. Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy. International Journal of Pharmaceutics 562 , pp.303-312. (10.1016/j.ijpharm.2019.03.041)
• Okosieme, O. E. et al. 2019. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes and Endocrinology 7 (4), pp.278-287. (10.1016/S2213-8587(19)30059-2)
• Draman, M. S. et al. 2019. Prostaglandin F2-alpha eye drops (bimatoprost) in Graves' orbitopathy: a randomized controlled double-masked crossover trial (BIMA Trial). Thyroid Journal Program 29 (4), pp.563-572. (10.1089/thy.2018.0506)
• Taylor, P. N. et al. 2019. Liothyronine cost and prescriptions in England. Lancet Diabetes and Endocrinology 7 (1), pp.11-12. (10.1016/S2213-8587(18)30334-6)

2018

• Muller, I. et al. 2018. Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy; evidence that TRAb may precede thyroid dysfunction by many years.. Thyroid 28 (12), pp.1682-1693. (10.1089/thy.2018.0232)
• Beltrami, C. et al., 2018. Association of elevated urinary miR-126, miR-155, and miR-29b with diabetic kidney disease. American Journal of Pathology 188 (9), pp.1982-1992. (10.1016/j.ajpath.2018.06.006)
• Powell, W. E. et al. 2018. Loss of CXCR3 expression on memory B cells in individuals with long-standing type 1 diabetes. Diabetologia 61 , pp.1794-1803. (10.1007/s00125-018-4651-x)
• Oakley, N. et al., 2018. The association between Type 1 diabetes mellitus and educational attainment in childhood: a systematic review protocol. BMJ Open 8 (8) e021893. (10.1136/bmjopen-2018-021893)
• Pariani, N. et al., 2018. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. Journal of Clinical Endocrinology & Metabolism 108 (8), pp.3010-3018. (10.1210/jc.2018-00359)
• Asderakis, A. et al. 2018. The influence of socioeconomic deprivation on outcomes in pancreas transplantation in England; Registry Data Analysis. American Journal of Transplantation 18 (6), pp.1380-1387. (10.1111/ajt.14633)
• Peterson, S. J. et al., 2018. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid 28 (6), pp.707. (10.1089/thy.2017.0681)
• Taylor, P. N. et al. 2018. Global epidemiology of hyperthyroidism and hypothyroidism. Nature Reviews Endocrinology 14 (5), pp.301-316. (10.1038/nrendo.2018.18)
• Hales, C. et al. 2018. Controlled antenatal thyroid screening II: effect of treating maternal sub-optimal thyroid function on child cognition. Journal of Clinical Endocrinology and Metabolism 103 (4), pp.1583-1591. (10.1210/jc.2017-02378)
• Rajendram, R. et al., 2018. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes and Endocrinology 6 (4), pp.299-309. (10.1016/S2213-8587(18)30021-4)
• Bravis, V. et al., 2018. Relationship between islet autoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohort. BMJ Open 8 (4) e020904. (10.1136/bmjopen-2017-020904)
• Dietrich, A. et al., 2018. Establishing the usefulness of the GO-QOL in a UK hospital-treated population with thyroid eye disease in the CIRTED trial. Psychology, Health and Medicine 23 (18), pp.1341-1355. (10.1080/13548506.2018.1503693)
• Wasag, D. R. et al. 2018. Excess all-cause mortality before age 30 in childhood onset type 1 diabetes: data from the Brecon Group Cohort in Wales. Archives of Disease in Childhood 103 (1), pp.44-48. (10.1136/archdischild-2016-312581)
• Dew, R. et al., 2018. Attitudes and perceptions of health professionals towards management of hypothyroidism in general practice: a qualitative interview study. BMJ Open 8 (2) e019970. (10.1136/bmjopen-2017-019970)

2017

• Dul, M. et al. 2017. Hydrodynamic gene delivery in human skin using a hollow microneedle device. Journal of Controlled Release 265 , pp.120-131. (10.1016/j.jconrel.2017.02.028)
• Zhao, X. et al. 2017. Formulation of hydrophobic peptides for skin delivery via coated microneedles. Journal of Controlled Release 265 , pp.2-13. (10.1016/j.jconrel.2017.03.015)
• Alhadj Ali, M. et al. 2017. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Science Translational Medicine 9 (402) eaaf7779. (10.1126/scitranslmed.aaf7779)
• Muller, I. et al. 2017. TPOAb and thyroid function are not associated with breast cancer outcome: evidence from a large-scale study using data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001). European Thyroid Journal 6 (4), pp.197-207. (10.1159/000460246)
• Taylor, P. N. et al. 2017. Maturation in serum thyroid function parameters over childhood and puberty: results of a longitudinal study. Journal of Clinical Endocrinology and Metabolism 102 (7), pp.2508-2515. (10.1210/jc.2016-3605)
• Dew, R. et al., 2017. Patients' attitudes and perceptions towards treatment of hypothyroidism in general practice: an in-depth qualitative interview study. BJGP Open BJGP-2017-0125. (10.3399/bjgpopen17X100977)
• Draman, M. S. et al. 2017. The role of thyrotropin receptor activation in adipogenesis and modulation of fat phenotype. Frontiers in Endocrinology 8 83. (10.3389/fendo.2017.00083)
• Alhadj Ali, M. et al. 2017. Factors influencing effective recruitment to phase 1 interventional trials in new-onset type 1 diabetes: analysis of 12 months referrals to diabetes research centre [Abstract]. Diabetic Medicine 34 (S1) P122. (10.1111/dme.16_13304)
• Dew, R. et al., 2017. Clinical, behavioural and pharmacogenomic factors influencing the response to levothyroxine therapy in patients with primary hypothyroidism-protocol for a systematic review. Systematic Reviews 6 (1) 60. (10.1186/s13643-017-0457-z)
• Mellington, F. E. et al., 2017. Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit. Orbit 36 (3), pp.159-169. (10.1080/01676830.2017.1280057)
• Alhadj Ali, M. et al. 2017. Use of a “YouTube” style video clip to raise interest amongst young people with new‐onset Type 1 diabetes in immunotherapy trials [Abstract]. Diabetic Medicine 34 (S1) P315. (10.1111/dme.24_13304)
• Arif, S. et al., 2017. β-cell specific T-lymphocyte response has a distinct inflammatory phenotype in children with Type 1 diabetes compared with adults. Diabetic Medicine 34 (3), pp.419-425. (10.1111/dme.13153)

2016

• Korevaar, T. I. et al., 2016. An invitation to join the consortium on thyroid and pregnancy [Letter]. European Thyroid Journal 5 (4), pp.277. (10.1159/000452331)
• Korevaar, T. I. M. et al., 2016. An invitation to join the consortium on thyroid and pregnancy [Letter]. Obstetrics and Gynaecology 128 (4), pp.913. (10.1097/AOG.0000000000001670)
• Tatovic, D. et al. 2016. Stimulated urine C-peptide creatinine ratio vs serum C-peptide level for monitoring of β-cell function in the first year after diagnosis of Type 1 diabetes. Diabetic Medicine 33 (11), pp.1564-1568. (10.1111/dme.13186)
• Eligar, V. et al. 2016. Thyroxine replacement: a clinical endocrinologists viewpoint. Annals of Clinical Biochemistry 53 (4), pp.421-433. (10.1177/0004563216642255)
• Vedhara, K. et al., 2016. Illness beliefs predict mortality in patients with diabetic foot ulcers. PLoS ONE 11 (4), pp.e0153315. (10.1371/journal.pone.0153315)
• Bartalena, L. et al., 2016. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy guidelines for the management of Graves' Orbitopathy. European Thyroid Journal 5 (1), pp.9-26. (10.1159/000443828)
• Alhadj Ali, M. et al. 2016. Assessing fear of hypoglycaemia in newly disgnosed patients with Type 1 diabetes. Diabetic Medicine 33 (1) P149. (10.1111/dme.20_13048)
• Muller, I. et al. 2016. The sodium iodide symporter is unlikely to be a thyroid/breast shared antigen. Journal of Endocrinological Investigation 39 (3), pp.323-331. (10.1007/s40618-015-0368-6)
• Zhao, X. et al. 2016. Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes. Journal of Controlled Release 223 , pp.178-187. (10.1016/j.jconrel.2015.12.040)
• Taylor, P. et al. 2016. Paradoxical relationship between body mass index and thyroid hormone levels: a study using Mendelian randomization. Journal of Clinical Endocrinology & Metabolism 101 (2), pp.730-738. (10.1210/jc.2015-3505)
• Okosieme, O. et al. 2016. Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. Clinical Endocrinology 84 (6), pp.799-808. (10.1111/cen.12824)

2015

• Alhadj Ali, M. et al. 2015. Topical steroid therapy induces pro-tolerogenic changes in Langerhans cells in human skin. Immunology 146 (3), pp.411-422. (10.1111/imm.12518)
• Perros, P. et al., 2015. Future research in Graves' Orbitopathy: from priority setting to trial design through patient and public involvement. Thyroid: official journal of the American Thyroid Association 25 (11), pp.1181-1184. (10.1089/thy.2015.0222)
• Zhang, L. et al. 2015. Reversal of pathological features of Graves' orbitopathy by activation of forkhead transcription factors, FOXOs. Journal of Clinical Endocrinology & Metabolism 101 (1), pp.114-122. (10.1210/jc.2015-2932)
• Perros, P. et al., 2015. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. British Journal of Ophthalmology 99 (11), pp.1531-1535. (10.1136/bjophthalmol-2015-306733)
• Dunseath, G. et al., 2015. Bridging-type enzyme-linked immunoassay for zinc transporter 8 autoantibody measurements in adult patients with diabetes mellitus. Clinica Chimica Acta 447 , pp.90-95. (10.1016/j.cca.2015.05.010)
• Tatovic, D. et al. 2015. Fine-needle aspiration biopsy of the lymph node: a novel tool for the monitoring of immune responses after skin antigen delivery. Journal of Immunology 195 (1), pp.386-392. (10.4049/jimmunol.1500364)
• Sayers, A. et al., 2015. Evidence for a persistent, major excess in all cause admissions to hospital in children with type-1 diabetes: results from a large Welsh national matched community cohort study. BMJ Open 5 e005644. (10.1136/bmjopen-2014-005644)
• Wolfe, A. et al., 2015. Bariatric surgery in morbidly obese insulin resistant humans normalises insulin signalling but not insulin-stimulated glucose disposal. PLoS ONE 10 (4), pp.1-10. e0120084. (10.1371/journal.pone.0120084)
• Perros, P. et al., 2015. Management of patients with Graves' orbitopathy: initial assessment, management outside specialised centres and referral pathways. Clinical Medicine 15 (2), pp.173-178. (10.7861/clinmedicine.15-2-173)
• Dhanda, A. D. et al., 2015. Long-term outcome in patients with severe alcoholic hepatitis can be reliably determined using anin vitromeasure of steroid sensitivity. Hepatology 61 (3), pp.1099. (10.1002/hep.27211)
• Mitchell, A. L. et al., 2015. Diagnosis of Graves' orbitopathy (DiaGO): results of a pilot study to assess the utility of an office tool for practicing endocrinologists. Journal of Clinical Endocrinology & Metabolism 100 (3), pp.E458-E462. (10.1210/jc.2014-3146)
• Skowera, A. et al., 2015. β-Cell-specific CD8 T Cell phenotype in Type 1 diabetes reflects chronic autoantigen exposure. Diabetes 64 (3), pp.916-925. (10.2337/db14-0332)

2014

• Taylor, P. N. et al. 2014. Maternal perchlorate levels in women with borderline thyroid function during pregnancy and the cognitive development of their offspring: data from the controlled antenatal thyroid study. Journal of Clinical Endocrinology and Metabolism 99 (11), pp.4291-4298. (10.1210/jc.2014-1901)
• Taylor, P. et al. 2014. TSH levels and risk of miscarriage in women on long-term levothyroxine: a community-based study. Journal of Clinical Endocrinology & Metabolism 99 (10), pp.3895-3902. (10.1210/jc.2014-1954)
• Vedhara, K. et al., 2014. Illness beliefs predict self-care behaviours in patients with diabetic foot ulcers: A prospective study. Diabetes Research and Clinical Practice 106 (1), pp.67-72. (10.1016/j.diabres.2014.07.018)
• Zhang, L. et al. 2014. Possible targets for nonimmunosuppressive therapy of Graves' orbitopathy. Journal of Clinical Endocrinology & Metabolism 99 (7), pp.E1183-E1190. (10.1210/jc.2013-4182)
• Muller, I. et al. 2014. Does thyroid peroxidase provide an antigenic link between thyroid autoimmunity and breast cancer?. International Journal of Cancer 134 (7), pp.1706-1714. (10.1002/ijc.28493)
• Taylor, P. et al. 2014. Therapy of endocrine disease: impact of iodine supplementation in mild-to-moderate iodine deficiency: systematic review and meta-analysis. European Journal of Endocrinology 170 (1), pp.R1-R15. (10.1530/EJE-13-0651)
• Taylor, P. N. et al. 2014. Falling threshold for treatment of borderline elevated thyrotropin levels - balancing benefits and risks: evidence from a large community-based study. JAMA Internal Medicine 174 (1), pp.32-39. (10.1001/jamainternmed.2013.11312)
• Hales, C. et al. 2014. The second wave of the Controlled Antenatal Thyroid Screening (CATS II) study: the cognitive assessment protocol. BMC Endocrine Disorders 14 (1) 95. (10.1186/1472-6823-14-95)

2013

• Draman, M. et al. 2013. Effects of Prostaglandin F2a on adipocyte biology relevant to graves' orbitopathy. Thyroid: official journal of the American Thyroid Association 23 (12), pp.1600-1608. (10.1089/thy.2013.0194)
• Taylor, P. et al. 2013. A review of the clinical consequences of variation in thyroid function within the reference range. Journal of Clinical Endocrinology & Metabolism 98 (9), pp.3562-3571. (10.1210/jc.2013-1315)
• Liu, Y. , Peakman, M. and Dayan, C. M. 2013. Safely targeting autoimmunity in type 1 diabetes: the MonoPepT1De trial. Practical Diabetes 30 (4), pp.148-150a. (10.1002/pdi.1764)
• Tatovic, D. et al. 2013. Topical steroid has the potential of modulating skin dendritic cells to tolerogenic antigen presenting cells in human organ skin bath culture [Abstract]. Diabetic Medicine 30 (s1), pp.53-53. (10.1111/dme.12091_1)
• Waheed, N. , Butt, M. and Dayan, C. M. 2013. Hypoglycaemia documented with real-time continuous glucose sensing in a case of 'dead in bed' syndrome. Practical Diabetes 30 (1), pp.33-35. (10.1002/pdi.1737)

2012

• Alhadj Ali, M. et al. 2012. Functional modulation of epidermal dendritic cells by topical steroid treatment to optimise the tolerogenic potential of immunotherapy for type 1 diabetes [Abstract]. Diabetologia 55 (S1), pp.S192. (10.1007/s00125-012-2688-9)
• Zhang, L. et al. 2012. Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves' orbitopathy. Journal of Clinical Endocrinology & Metabolism 97 (2), pp.653-662. (10.1210/jc.2011-1299)
• Dawson, C. et al., 2012. NFκB and glucocorticoid receptor activity in steroid resistance. Journal of Receptors and Signal Transduction 32 (1), pp.29-35. (10.3109/10799893.2011.641977)
• Kronenberg, D. et al., 2012. Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill β-cells. Diabetes 61 (7), pp.1752-1759. (10.2337/db11-1520)
• Perros, P. et al., 2012. Orbital decompression for Graves' orbitopathy in England. Eye 26 (3), pp.434-437. (10.1038/eye.2011.323)
• Raghavan, R. P. et al., 2012. Amiodarone-induced thyrotoxicosis, an overview of UK management [Letter]. Clinical Endocrinology 77 (6), pp.936-937. (10.1111/j.1365-2265.2012.04435.x)
• Sands, B. E. et al., 2012. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology 143 (2), pp.356-364. (10.1053/j.gastro.2012.04.043)
• Vedhara, K. et al., 2012. Development and preliminary evaluation of a psychosocial intervention for modifying psychosocial risk factors associated with foot re-ulceration in diabetes. Behaviour Research and Therapy 50 (5), pp.323-332. (10.1016/j.brat.2012.02.013)

2011

• Alhadj Ali, M. et al. 2011. Optimizing the tolerogenic potential of a 'vaccine' for type 1 diabetes by topical betamethasone therapy [Abstract]. Diabetologia 54 (S1), pp.S88-S89. (10.1007/s00125-011-2276-4)
• Alhadj Ali, M. et al. 2011. Effects of topical steroid and vitamin D therapy in optimizing the tolerogenic potential of a 'vaccine' for type 1 diabetes. Diabetic Medicine 28 (S1), pp.80. (10.1111/j.1464-5491.2011.03233_1.x)
• Andrews, R. C. et al., 2011. Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: The Early ACTID randomised controlled trial. The Lancet 378 (9786), pp.129-139. (10.1016/S0140-6736(11)60442-X)
• Arif, S. et al., 2011. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death. Diabetes 60 (8), pp.2112-2119. (10.2337/db10-1643)
• Bould, H. et al., 2011. Investigation of thyroid dysfunction is more likely in patients with high psychological morbidity. Family Practice 29 (2), pp.163-167. (10.1093/fampra/cmr059)
• Cooper, A. R. et al., 2011. Sedentary time, breaks in sedentary time and metabolic variables in people with newly diagnosed type 2 diabetes. Diabetologia 55 (3), pp.589-599. (10.1007/s00125-011-2408-x)
• di Mambro, A. J. et al., 2011. In vitro steroid resistance correlates with outcome in severe alcoholic hepatitis. Hepatology 53 (4), pp.1316-1322. (10.1002/hep.24159)
• Hermanides, J. et al., 2011. Sensor-augmented pump therapy lowers HbA1c in suboptimally controlled Type-1 diabetes; a randomized controlled trial. Diabetic Medicine 28 (10), pp.1158-1167. (10.1111/j.1464-5491.2011.03256.x)
• Mallone, R. et al., 2011. Immunology of diabetes society T-Cell workshop: HLA class I tetramer-directed epitope validation initiative T-Cell workshop report-HLA class I tetramer validation initiative. Diabetes/Metabolism Research and Reviews 27 (8), pp.720-726. (10.1002/dmrr.1243)
• Rajendram, R. et al., 2011. Smoking and strabismus surgery in patients with thyroid eye disease. Ophthalmology 118 (12), pp.2493-2497. (10.1016/j.ophtha.2011.06.003)
• Taylor, P. N. et al., 2011. A meta-analysis of the associations between common variation in the PDE8B gene and thyroid hormone parameters, including assessment of longitudinal stability of associations over time and effect of thyroid hormone replacement. European Journal of Endocrinology 164 (5), pp.773-780. (10.1530/EJE-10-0938)
• Walsh, J. P. et al., 2011. The clinical presentation of autoimmune thyroid disease in men is associated with IL12B genotype. Clinical Endocrinology 74 (4), pp.508-512. (10.1111/j.1365-2265.2010.03970.x)

2010

• Petrich de Marquesini, L. G. et al., 2010. IFN-γ and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes. Diabetologia 53 (7), pp.1451-1460. (10.1007/s00125-010-1739-3)
• Rees, D. A. and Dayan, C. M. 2010. Commentary: Testosterone and the metabolic syndrome: cause or consequence?. International Journal of Epidemiology 40 (1), pp.207-209. (10.1093/ije/dyq254)
• Vedhara, K. et al., 2010. Coping style and depression influence the healing of diabetic foot ulcers: observational and mechanistic evidence. Diabetologia 53 (8), pp.1590-1598. (10.1007/s00125-010-1743-7)

2009

• Alhadj Ali, M. and Dayan, C. M. 2009. Review: The importance of residual endogenous beta-cell preservation in type 1 diabetes. British Journal of Diabetes and Vascular Disease 9 (6), pp.248-253. (10.1177/1474651409351881)
• Panicker, V. et al., 2009. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. Journal of Clinical Endocrinology & Metabolism 94 (5), pp.1623-1629. (10.1210/jc.2008-1301)
• Allen, J. S. et al., 2009. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of Type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes 58 (1), pp.138-145. (10.2337/db08-0964)
• Creed, T. J. et al., 2009. The effects of cytokines on suppression of lymphocyte proliferation by dexamethasone. The Journal of Immunology 183 (1), pp.164-171. (10.4049/jimmunol.0801998)
• Dayan, C. M. and Panicker, V. 2009. Novel insights into thyroid hormones from the study of common genetic variation. Nature Reviews Endocrinology 5 (4), pp.211-218. (10.1038/nrendo.2009.19)
• Estcourt, S. et al., 2009. The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey. European Journal of Endocrinology 161 (3), pp.483-487. (10.1530/EJE-09-0383)
• Lee, R. W. J. et al., 2009. Steroid refractory CD4+ T Cells in patients with sight-threatening uveitis. Investigative Ophthalmology and Visual Science 50 (9), pp.4273-4278. (10.1167/iovs.08-3152)
• Panicker, V. et al., 2009. A paradoxical difference in relationship between anxiety, depression and thyroid function in subjects on and not on T4: findings from the HUNT study. Clinical Endocrinology 71 (4), pp.574-580. (10.1111/j.1365-2265.2008.03521.x)
• Thrower, S. L. et al., 2009. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clinical and Experimental Immunology 155 (2), pp.156-165. (10.1111/j.1365-2249.2008.03814.x)
• Williams, M. D. et al., 2009. Thyroid function and the natural history of depression: findings from the Caerphilly Prospective Study (CaPS) and a meta-analysis. Clinical Endocrinology 70 (3), pp.484-492. (10.1111/j.1365-2265.2008.03352.x)

2008

• Panicker, V. et al., 2008. A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. Journal of Clinical Endocrinology & Metabolism 93 (8), pp.3075-3081. (10.1210/jc.2008-0397)
• Melzer, D. et al., 2008. A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genetics 4 (5) e1000072. (10.1371/journal.pgen.1000072)
• Baker, C. et al., 2008. Human CD8 responses to a complete epitope set from preproinsulin: implications for approaches to epitope discovery. Journal of Clinical Immunology 28 (4), pp.350-360. (10.1007/s10875-008-9177-4)
• Dayan, C. M. and Wraith, D. C. 2008. Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412. Clinical and Experimental Immunology 151 (2), pp.231-234. (10.1111/j.1365-2249.2007.03559.x)
• Lawson, J. M. et al., 2008. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clinical and Experimental Immunology 154 (3), pp.353-359. (10.1111/j.1365-2249.2008.03810.x)
• Searle, A. et al., 2008. Reducing the burden of chronic wounds: prevention and management of the diabetic foot in the context of clinical guidelines. Journal of Health Services Research and Policy 13 (Supp 3), pp.82-91. (10.1258/jhsrp.2008.008011)
• Searle, A. et al., 2008. Do patients’ beliefs about type 2 diabetes differ in accordance with complications: An investigation into diabetic foot ulceration and retinopathy. International Journal of Behavioral Medicine 15 (3), pp.173-179. (10.1080/10705500802212940)
• Skowera, A. et al., 2008. CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. Journal of Clinical Investigation 118 (10), pp.3390-3402. (10.1172/JCI35449)
• Wong, F. S. and Dayan, C. M. 2008. Regulatory T cells in autoimmune endocrine diseases. Trends in Endocrinology & Metabolism 19 (8), pp.292-299. (10.1016/j.tem.2008.07.007)

2007

• Baker, C. et al., 2007. Activated T cell subsets in human type 1 diabetes: evidence for expansion of the DR+ CD30+ subpopulation in new-onset disease. Clinical and Experimental Immunology 147 (3), pp.472-482. (10.1111/j.1365-2249.2006.03307.x)
• Dayan, C. M. and Dayan, M. R. 2007. Dysthyroid optic neuropathy: a clinical diagnosis or a definable entity?. British Journal of Ophthalmology 91 (4), pp.409-410. (10.1136/bjo.2006.110932)
• Jun-Fen, F. et al., 2007. Kikuchi-Fujimoto disease manifesting as recurrent thrombocytopenia and Mobitz type II atrioventricular block in a 7-year-old girl: a case report and analysis of 138 Chinese childhood Kikuchi-Fujimoto cases with 10 years of follow-up in 97 patients [review]. Acta Paediatrica 96 (12), pp.1844-1847. (10.1111/j.1651-2227.2007.00523.x)
• Lee, R. W. J. et al., 2007. CD4+CD25int T cells in inflammatory diseases refractory to treatment with glucocorticoids. The Journal of Immunology 179 (11), pp.7941-7948. (10.4049/jimmunol.179.11.7941)
• Saravanan, P. et al., 2007. Twenty-four hour hormone profiles of TSH, free T3 and free T4 in hypothyroid patients on combined T3/T4 therapy. Experimental and Clinical Endocrinology & Diabetes 115 (4), pp.261-267. (10.1055/s-2007-973071)
• Williams, A. J. K. et al., 2007. Magnetic resonance imaging: a reliable method for measuring pancreatic volume in Type 1 diabetes. Diabetic Medicine 24 (1), pp.35-40. (10.1111/j.1464-5491.2007.02027.x)

2006

• Creed, T. J. et al., 2006. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Alimentary Pharmacology and Therapeutics 23 (10), pp.1435-1442. (10.1111/j.1365-2036.2006.02904.x)
• Fu, J. F. et al., 2006. Early activation of the inhibin B/FSH axis in obese Tanner stage G1PH1 boys. Clinical Endocrinology -Oxford- 65 (3), pp.327-332. (10.1111/j.1365-2265.2006.02597.x)
• Saravanan, P. , Visser, T. J. and Dayan, C. M. 2006. Psychological well-being correlates with free thyroxine but not free 3,5,3′-triiodothyronine levels in patients on thyroid hormone replacement. Journal of Clinical Endocrinology & Metabolism 91 (9), pp.3389-3392. (10.1210/jc.2006-0414)

2005

• Saravanan, P. et al., 2005. Partial substitution of Thyroxine (T4) with Tri-Iodothyronine in patients on T4Replacement therapy: results of a large community-based randomized controlled trial. Journal of Clinical Endocrinology & Metabolism 90 (2), pp.805-812. (10.1210/jc.2004-1672)

2004

• Arif, S. et al., 2004. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. The Journal of Clinical Investigation 113 (3), pp.451-463. (10.1172/JCI19585)
• Lindley, S. et al., 2004. Defective suppressor function in CD4+CD25+ T-cells from patients with type 1 diabetes. Diabetes 54 (1), pp.92-99. (10.2337/diabetes.54.1.92)
• Narendran, P. et al., 2004. Dendritic cell-based assays, but not mannosylation of antigen, improves detection of T-cell responses to proinsulin in type 1 diabetes. Immunology 111 (4), pp.422-429. (10.1111/j.1365-2567.2004.01825.x)

2003

• Baker, C. et al., 2003. Corticotropin-releasing hormone immunoreactivity in human T and B cells and macrophages: colocalization with arginine vasopressin. Journal of Neuroendocrinology 15 (11), pp.1070-1074. (10.1046/j.1365-2826.2003.01099.x)
• Creed, T. J. et al., 2003. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Alimentary Pharmacology and Therapeutics 18 (1), pp.65-75. (10.1046/j.1365-2036.2003.01639.x)
• Dayan, C. M. 2003. Human monoclonal thyroid-stimulating autoantibody: how useful is a holy grail?. The Lancet 362 (9378), pp.92-93. (10.1016/S0140-6736(03)13893-7)
• Dayan, C. M. 2003. Misconceptions in thyroid eye disease. Practitioner 247 (1648), pp.576-580.
• Finucane, K. et al., 2003. Insulin injection abscesses caused by Mycobacterium chelonae [letter]. Diabetes Care 26 (8), pp.2483-2484. (10.2337/diacare.26.8.2483)
• Narendran, P. et al., 2003. Humoral and cellular immune responses to proinsulin in adults with newly diagnosed type 1 diabetes. Diabetes/Metabolism Research and Reviews 19 (1), pp.52-59. (10.1002/dmrr.332)

2002

• Dayan, C. M. and Lightman, S. A. 2002. Pharmacotherapeutics and the endocrine system: blocking, replacing and exploiting nature's magic bullets. Current Opinion in Pharmacology 2 (6), pp.691-693. (10.1016/S1471-4892(02)00223-0)
• Dayan, C. M. , Saravanan, P. and Bayly, G. 2002. Whose normal thyroid function is better—yours or mine?. The Lancet 360 (9330), pp.353-354. (10.1016/S0140-6736(02)09602-2)
• Lambert, A. P. et al., 2002. Reproducibility of individualized coronary heart disease risk calculations in patients with diabetes mellitus. Diabetic Medicine 19 (6), pp.514-517. (10.1046/j.1464-5491.2002.00687.x)
• Saravanan, P. et al., 2002. Psychological well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clinical Endocrinology 57 (5), pp.577-585. (10.1046/j.1365-2265.2002.01654.x)
• Varela-Calvino, R. et al., 2002. Characterization of the T-cell response to coxsackievirus B4: evidence that effector memory cells predominate in patients with type 1 diabetes. Diabetes 51 (6), pp.1745-1753. (10.2337/diabetes.51.6.1745)

2001

• Dayan, C. M. 2001. Interpretation of thyroid function tests. The Lancet 357 (9256), pp.619-624. (10.1016/S0140-6736(00)04060-5)
• Dayan, C. M. 2001. Stressful life events and Graves' disease revisited [editorial]. Clinical Endocrinology 55 (1), pp.13-14. (10.1046/j.1365-2265.2001.01289.x)
• Peakman, M. and Dayan, C. M. 2001. Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?. Immunology 104 (4), pp.361-366. (10.1046/j.1365-2567.2001.01335.x)
• Saravanan, P. and Dayan, C. M. 2001. Thyroid autoantibodies [review]. Endocrinology and Metabolism Clinics of North America 30 (2), pp.315-337.
• Varela-Calvino, R. et al., 2001. T Cell activation by coxsackievirus B4 antigens in type 1 diabetes mellitus: evidence for selective TCR V  usage without superantigenic activity. The Journal of Immunology 167 (6), pp.3513-3520. (10.4049/jimmunol.167.6.3513)

2000

• Hearing, S. D. et al., 2000. Lymphocyte steroid sensitivity (LSS) in remission and outcome of steroid therapy for severe ulcerative colitis (UC). Gastroenterology 118 (4), pp.A791. (10.1016/s0016-5085(00)85306-8)
• Maile, R. et al., 2000. Effective formation of major histocompatibility complex class II-peptide complexes from endogenous antigen by thyroid epithelial cells. Immunology 99 (3), pp.367-374. (10.1046/j.1365-2567.2000.00958.x)
• Walsh, J. P. and Dayan, C. M. 2000. Role of biochemical assessment in management of corticosteroid withdrawal [review]. Annals of Clinical Biochemistry 37 (3), pp.279-288. (10.1258/0004563001899410)

1999

• Ahlquist, J. , Walsh, J. P. and Dayan, C. M. 1999. Radioiodine and thyroid eye disease - Reply. BMJ 319 (7217), pp.1133-1133. (10.1136/bmj.319.7217.1133a)
• Walsh, J. P. , Dayan, C. M. and Potts, M. J. 1999. Radioiodine and thyroid eye disease - Use with caution. BMJ 319 (7202), pp.68-69. (10.1136/bmj.319.7202.68)
• Hearing, S. D. , Norman, M. and Dayan, C. M. 1999. In vitro measurement of lymphocyte steroid sensitivity: lack of agreement between whole blood culture and separated lymphocyte culture. Immunopharmacology and Immunotoxicology 21 (1), pp.41-53. (10.3109/08923979909016393)
• Hearing, S. D. et al., 1999. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 45 (3), pp.382-388. (10.1136/gut.45.3.382)
• Hearing, S. D. et al., 1999. Wide variation in lymphocyte steroid sensitivity among healthy human volunteera. Journal of Clinical Endocrinology and Metabolism 84 (11), pp.4149-4154. (10.1210/jc.84.11.4149)

1998

• Leech, N. J. and Dayan, C. M. 1998. Controversies in the management of Graves' disease [review]. Clinical Endocrinology -Oxford- 49 (3), pp.273-280. (10.1046/j.1365-2265.1998.00558.x)

1997

• Dayan, C. M. , Elsegood, K. A. and Maile, R. 1997. FasL expression on epithelial cells: the Bottazzo-Feldman hypothesis revisited [review]. Immunology Today 18 (5), pp.203. (10.1016/s0167-5699(97)81661-1)
• Jessop, D. S. et al., 1997. Effects of Acute Stress or Centrally Injected Interleukin-1beta on Neuropeptide Expression in the Immune System. Stress -Basel- 2 (2), pp.133-144. (10.3109/10253899709014744)
• Jessop, D. S. et al., 1997. An antisense oligodeoxynucleotide complementary to corticotropin-releasing hormone mRNA inhibits rat splenocyte proliferation in vitro. Journal of Neuroimmunology 75 (1-2), pp.135-140. (10.1016/s0165-5728(97)00011-8)
• Maile, R. , Elsegood, K. A. and Dayan, C. M. 1997. Functionality of inducible major histocompatibility class II expression by specialised non-lymphoid cells. Biochemical Society Transactions 25 (2), pp.318S.

1996

• Dayan, C. M. and Daniels, G. 1996. Chronic autoimmune thyroiditis [review]. New England Journal of Medicine 335 (2), pp.99-107. (10.1056/nejm199610033351425)
• Quaratino, S. et al., 1996. Human self-reactive T cell clones expressing identical T cell receptor beta chains differ in their ability to recognize a cryptic self-epitope. Journal of Experimental Medicine 183 (2), pp.349-358. (10.1084/jem.183.2.349)
• Dayan, C. M. et al. 1996. Biochemical cure of recurrent acromegaly by resection of cervical spinal canal metastases. Clinical Endocrinology -Oxford- 44 (5), pp.597-602. (10.1046/j.1365-2265.1996.685507.x)

1995

• Dayan, C. M. and Jackson, M. 1995. The 1995 Advanced Medicine Conference [congress]. Clinical Medicine - London 29 (4), pp.344-348.
• Mullins, R. J. et al., 1995. Identification of thyroid stimulating hormone receptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines. The Journal of Clinical Investigation 96 (1), pp.30-37. (10.1172/jci118034)
• Wong, N. A. et al., 1995. Acute respiratory distress secondary to Morgagni diaphragmatic herniation in an adult. Postgraduate Medical Journal -London- 71 (831), pp.39-41. (10.1136/pgmj.71.831.39)

1994

• Mullins, R. J. et al., 1994. Transfection of thyroid autoantigens into EBV-transformed B cell lines. recognition by Graves' disease thyroid T cells. The Journal of Immunology 152 (11), pp.5572-5580.

1993

• Dayan, C. M. et al. 1993. T cells involved in human autoimmune disease are resistant to tolerance induction. The Journal of Immunology 151 (3), pp.1606-1613.
• Quaratino, S. et al., 1993. Definition of the tri-molecular complex of human thyroid peroxidase specific autoreactive t-cell clones. Journal of Cellular Biochemistry 17 (Supp C), pp.72-72.
• Dayan, C. M. 1993. Provider power: an important lesson from the US health care market. Clinical Medicine 27 (3), pp.238-241.
• Lehmann, P. V. et al., 1993. Determinant spreading and the dynamics of the autoimmune T-cell repertoire [review]. Immunology Today 14 (5), pp.203-208. (10.1016/0167-5699(93)90163-f)

1992

• Dayan, C. M. et al. 1992. Autoimmune thyroiditis and targeted anti-T cell immunotherapy in man [review]. Autoimmunity 11 (3), pp.189-198. (10.3109/08916939209035154)
• Feldmann, M. et al., 1992. Mechanism of Graves thyroiditis: implications for concepts and therapy of autoimmunity [Review]. International Reviews of Immunology 9 (2), pp.91-106. (10.3109/08830189209061785)

1991

• Dayan, C. M. et al. 1991. Autoantigen recognition by thyroid-infiltrating T cells in Graves disease. Proceedings of the National Academy of Sciences of the United States of America 88 (16), pp.7415-7419. (10.1073/pnas.88.16.7415)

1990

• Zheng, R. Q. et al., 1990. Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3 on human thyroid epithelial cells in Graves' and Hashimoto's diseases. Journal of Autoimmunity 3 (6), pp.727-736. (10.1016/s0896-8411(05)80039-3)